Veena Shankaran, MD

Veena Shankaran MD

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-830
Seattle, WA 98109-1023

Admin Contact

Lillianne Lui

Specialty / Expertise

Gastrointestinal Cancers

Research Interests

Gastrointestinal Cancers Trials, GI Cancer Related Health Outcomes, Comparative Effectiveness, Cost-Effectiveness of Cancer Therapies.

Current Research Projects

  • Aug 2012 – July 2014  
  • Implementation of a Prospective Financial Impact Assessment Tool in Colorectal Cancer
  • Funding Source: Southwest Oncology Group (SWOG) Coltman Fellowship
  • Local PI:  Veena Shankaran, MD
  • Funding Amount: $100,000
  • Status: Active
  • Feb 2011 – Dec 2012 
  • Adverse Events Associated with Newer Agents in Metastatic Colorectal Cancer.
  • Funding Source:  Genentech
  • PI:  Scott Ramsey, MD PhD;  Co-Investigator:  Veena Shankaran, MD
  • Funding Amount: $100,000
  • Status: Active
  • Jun 2011 Jun 2013
  • JVBB Ramucirumab CRC: Protocol I4T-MC-JVBB (also known as IMCL CP12-0920): A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma.
  • Funding Source: Eli Lilly and Company
  • Local PI: Veena Shankaran, MD
  • Funding Amount: $255,869
  • Status: Active


Dr. Shankaran received her Masters in Pharmaceutical Outcomes Research & Policy from the University of Washington. She received her MD from University of Michigan, Ann Arbor, MI. She completed her Internal Medicine Residency at University of Michigan, Ann Arbor, MI. She was a Post-Doctoral Fellow in Hematology/Oncology at Northwestern University, Chicago, IL.

Selected Publications

Shankaran V., Obel, J., Benson, A. Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions. The Oncologist. 2010 February; 15(2). (PMID: 20133499)

Shankaran V, Luu H, Nonzee N. Costs and Cost-Effectiveness of a Health Care Provider-Directed Intervention to Improve Colorectal Cancer Screening. Journal of Clinical Oncology. 2009 November; 27(32):5370-7375. (PMID: 19826133)

Shankaran V, Khrizman P, Benson AB. Risk Assessment and Adjuvant Systemic Therapy in Resected Stage II Colon Cancer. Current Colorectal Cancer Reports. 2009 Jul; 5 (3):158-165.

Shankaran V, Wisinski KB, Mulcahy MF, Benson AB. The Role of Molecular Markers in Predicting Response to Therapy in Patients with Colorectal Cancer. Molecular Diagnosis and Therapy. 12(2):87-98, 2008. (PMID: 18422373)

Shankaran V, McKoy JM, Dandade N, et al. Costs and Cost Effectiveness of a Low Intensity Patient-Directed Intervention to Promote Colorectal Cancer Screening. Journal of Clinical Oncology. 2007 Nov 20; 25(33): 5248-53. (PMID: 18024871)

Last updated: Dec 2012